PRKCQ

Across TCGA pan-cancer cohorts, PRKCQ mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PRKCQ data layer compared with 20 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PRKCQ mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PRKCQ expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where PRKCQ mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.711	0.927	.017	25	view →
LSCC	OS	Tertile	II,III,IV	0.734	1.000	.004	19	view →
LUAD	OS	Median	II,III,IV	0.850	1.000	.003	10	view →
GBM	OS	Median	All	0.963	0.774	.017	5	view →
CCRCC	OS	Tertile	All	1.000	0.562	.043	1	view →
HNSC	DFS	Tertile	III,IV	1.000	0.911	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRKCQ–PDAC (OS)

Open the PDAC breakdown →